Examples of intended areas of research of the new Laboratory of Molecular Imaging and Nanomedicine include: 1) Molecular Imaging Probe Development--Developing molecular imaging probes for in vivo imaging of biochemical processes, including positron emission tomography, optical imaging (fluorescence and Raman), magnetic resonance imaging, contrast enhanced ultrasound, photoacoustic and multimodal imaging. Molecular imaging in combination with anatomic and functional imaging can improve understanding of disease, enable early detection, and enhance monitoring of therapeutic responses and drug discovery and development. Methods include chemical synthesis, protein engineering, bioconjugation, radiolabeling, chemical analysis, preclinical studies, and clinical translation using various in vitro and in vivo techniques. 2) Nano Theranostics--Rational design of water-soluble, biocompatible nanoparticles for combined imaging and therapy. Nanoparticles (<100nm) synthesized from materials such as polymers, metals, ceramics and lipids permit simultaneous diagnostic imaging, drug delivery, and monitoring of therapeutic responses. Methods include synthesis, physiochemical characterization, surface modification and bioconjugation, pharmacokinetic, and pharmacodynamic evaluation in rodents for translation to clinical application.

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2009
Total Cost
$1,912,399
Indirect Cost
Name
National Institute of Biomedical Imaging and Bioengineering
Department
Type
DUNS #
City
State
Country
Zip Code
Xie, Jin; Lee, Seulki; Chen, Xiaoyuan (2010) Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 62:1064-79
Wang, Kezheng; Wang, Kai; Li, Weihual et al. (2009) Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 50:1095-103
Lee, Seulki; Ryu, Ju Hee; Park, Kyeongsoon et al. (2009) Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett 9:4412-6